Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma”

2 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 2 of 2 results

Testing effectiveness (Phase 2)Looking for participantsNCT07439653
What this trial is testing

TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

Who this might be right for
Histologically Confirmed Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
TORL Biotherapeutics, LLC 155
Testing effectiveness (Phase 2)UnknownNCT05050630
What this trial is testing

Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Who this might be right for
Age Range ≥16 Years, Gender UnlimitedHistopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell LymphomaReceived Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed+4 more
Affiliated Hospital to Academy of Military Medical Sciences
73